Published: 15 July 2014
Author(s): J.S. Koskinas, M. Deutsch, S. Adamidi, M. Skondra, M. Tampaki, A. Alexopoulou, S. Manolakopoulos, D. Pectasides

Patients who present HBV reactivation during immunosuppressive treatment are prone to develop life threatening decompensation of the liver function, therefore prophylaxis and treatment are strongly recommended. So far there are no data regarding the role of tenofovir in this context. Therefore, the aim of our study was to describe our “real life” experience with the use of tenofovir (TDF) in patients who underwent immunosuppressive treatment.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.